ArticleEuropean journal of immunology2010
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
Article in European journal of immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Circulating CD4Medicina (Kaunas, Lithuania) · 2023Article
- Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype.Human vaccines & immunotherapeutics · 2022Article
- Neuroprotection against ischemic stroke requires a specific class of early responder T cells in mice.The Journal of clinical investigation · 2022Article
- Cytolytic CD4Frontiers in immunology · 2022Review
- Evolutionary genetic algorithm identifiesNAR genomics and bioinformatics · 2021Article
- Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Formation of a Unique Population of CD8+ T Lymphocytes after Adoptive Transfer of Syngeneic Splenocytes to Mice with Lymphopenia.Doklady. Biochemistry and biophysics · 2021Article
- Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.Advances in experimental medicine and biology · 2021Article
- Resveratrol exerts antitumor effects by downregulating CD8Oncoimmunology · 2020Article
- Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.Human vaccines & immunotherapeutics · 2020Article
- Future prospects for CD8Immunological reviews · 2019Review
- Description of CD8Journal of immunology research · 2018Review
- Herbal Components of a Novel Formula PSORI-CM02 Interdependently Suppress Allograft Rejection and Induce CD8+CD122+PD-1+ Regulatory T Cells.Frontiers in pharmacology · 2018Article
- Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment.Oncotarget · 2017Article
- Chinese medicineOncotarget · 2017Article
- Article
- Editorial: Memory T Cells: Effectors, Regulators, and Implications for Transplant Tolerance.Frontiers in immunology · 2016Article
- CD8(+)CD122(+) T-Cells: A Newly Emerging Regulator with Central Memory Cell Phenotypes.Frontiers in immunology · 2015Review
- A naturally occurring CD8(+)CD122(+) T-cell subset as a memory-like Treg family.Cellular & molecular immunology · 2014Review
- Role of CD8(+) regulatory T cells in organ transplantation.Burns & trauma · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Lymphodeleption prior to adoptive transfer of tumor-specific T cells greatly improves the clinical efficacy of adoptive T-cell therapy for patients with advanced melanoma, and increases the therapeutic efficacy of cancer vaccines in animal models. Lymphodepletion reduces competition between lymphocytes, and thus creates "space" for enhanced expansion and survival of tumor-specific T cells. Within the lymphodepleted host, Ag-specific T cells still need to compete with other lymphocytes that undergo lymphopenia-driven proliferation. Herein, we describe the relative capacity of naïve T cells, Treg, and NK cells to undergo lymphopenia-driven proliferation. We found that the major population that underwent lymphopenia-driven proliferation was the CD122+ memory-like T-cell population (CD122+CD8+ Treg), and these cells competed with Ag-driven proliferation of melanoma-specific T cells. Removal of CD122+CD8+ Treg resulted in a greater expansion of tumor-specific T cells and tumor infiltration of functional effector/memory T cells. Our results demonstrate the lymphopenia-driven proliferation of CD122+CD8+ Treg in reconstituted lymphodepleted mice limited the antitumor efficacy of DC vaccination in conjunction with adoptive transfer of tumor-specific T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.